Ah, the markets. A bastion of rationality, predictability, and calm, right? Not when Donald J. Trump is in the driver’s seat, or even just tweeting from the back. The year 2025 has proven to be yet another masterclass in market volatility, where a single pronouncement can send trillions soaring or plummeting, often with the same dizzying speed as a Truth Social post going viral. Investors, bless their hearts, have spent the better part of the year clutching their pearls and portfolios, trying to decipher whether the latest presidential declaration is a harbinger of doom or an unexpected windfall. Spoiler alert: it’s usually both, sometimes simultaneously.
The Truth About Truth Social: From Social Scraps to Nuclear Dreams
Let’s kick things off with the platform that truly embodies the Trumpian market ethos: Truth Social. Or rather, its parent company, Trump Media & Technology Group (DJT). In a move that surprised precisely no one who follows the former (and current) President, his net worth reportedly surged by over $500 million in a single day thanks to DJT going public. Because, of course, a social media platform that primarily caters to a specific political base is exactly where one expects a multi-billion dollar valuation to materialize overnight.
But wait, there’s more! Just when you thought DJT was merely a digital soapbox, it pulled a rabbit out of a hat – or perhaps a fusion reactor out of thin air. On December 19, 2025, DJT stock surged an impressive 13.03% following the announcement of a strategic merger with TAE Technologies, a privately held nuclear fusion company. Not content with just owning a social media platform, Trump Media is now apparently in the business of harnessing the power of the sun. On December 18, DJT closed at $16.80, marking an “astounding rise”, and even surged 37% in early trading that day, aiming to create one of the world’s first publicly traded fusion companies. The stock closed up 42% on Thursday, December 18, at $14.86, with a trading volume of 99.5 million shares, a staggering 1,265% above its three-month average. One can only assume the market was reacting to the sheer audacity of a social media company pivoting to fusion energy. Or perhaps it was simply following the President’s direct advice: on April 9, Trump himself posted on Truth Social, “THIS IS A GREAT TIME TO BUY!!! DJT.” The market, ever obedient, delivered a massive surge. Despite this recent nuclear-powered enthusiasm, it’s worth noting that DJT stock is still down a rather significant 58% over the last year. A minor detail, one might say, when you’re busy chasing fusion dreams.
The Tariff Tango: Two Steps Forward, One Step Back (with a 10% Surcharge)
If there’s one policy that defines the Trump administration’s economic playbook, it’s tariffs. And 2025 has been no exception, delivering a masterclass in how to induce market whiplash with a single stroke of a pen – or, more accurately, a single Truth Social post. On April 2, President Trump unveiled a sweeping new trade policy, slapping a universal 10% tariff on all US imports, alongside “significantly higher ‘reciprocal tariffs'” on various trading partners. China, for instance, found itself staring down a cumulative 104% tariff, the European Union a modest 20%, and Japan a manageable 24%. This pushed the overall effective US tariff rate to approximately 25%, a level not seen in over a century.
The market, naturally, reacted with the grace of a brick falling off a skyscraper. The S&P 500 plunged by more than 10% over the following two days, effectively wiping out a cool $5 trillion from global markets. The Nasdaq Composite sank 3.56%, and the Dow Jones Industrial Average shed 879 points, or 1.9%, following a specific threat of “massive” tariffs on Chinese products. Industries felt the pinch, with reports of Jim Beam shutting down bourbon production due to trade wars with Canada and other countries. The irony, of course, is that while some industries were crippled, Americans were reportedly “getting a little bit more comfortable” with the tariff impacts. One wonders if “comfortable” is a euphemism for “resigned.”
But fear not, for the market giveth as quickly as the market taketh away. Just a week later, on April 9, the White House abruptly announced a 90-day pause on nearly all new reciprocal tariffs (excluding China). The result? An unprecedented market rebound. The S&P 500 surged 9.52%, the Nasdaq exploded 12.16% higher, and the Dow Jones jumped nearly 3,000 points. It’s almost as if the market thrives on uncertainty, then celebrates the temporary removal of said uncertainty. Analysts, ever the pragmatists, have noted a phenomenon of “tariff fatigue” but warn that “sudden announcements or changes in tone could still spark short-term swings.” JPMorgan even went so far as to highlight that posts on tariffs have been the “biggest market movers.” Because nothing says stable economic policy like a market held hostage by a character limit.
Big Pharma’s Bitter Pill: Discounts and Exemptions
The pharmaceutical industry, long a target for its pricing practices, found itself squarely in the President’s crosshairs this year. On December 19, 2025, Trump announced new drug pricing deals with nine major pharmaceutical companies, including heavyweights like Amgen, Bristol Myers Squibb, GSK, Merck (MRK), Novartis, and Sanofi. These companies, apparently eager to avoid the wrath of the tariff man, agreed to lower Medicaid drug prices to align with international rates and to sell medications directly through the soon-to-be-launched “TrumpRx” platform.
Merck (MRK), for example, announced a deal on December 19, promising approximately 70% discounts on its diabetes treatments like Januvia, Janumet, and Janumet XR for eligible patients. At the time, MRK was trading at $102.11 with a market cap of $253.34 billion. Not to be outdone, Pfizer (PFE) had already struck a similar deal on September 30, agreeing to “significant drug price cuts” and committing a hefty $70 billion investment into U.S. research and domestic manufacturing. Predictably, PFE stock responded favorably, rising about 5.3% that day, closing near $25.05 per share. The sweetener for these pharmaceutical giants? A three-year exemption from Section 232 tariffs. So, while the public gets cheaper drugs (allegedly), pharma companies get a pass on tariffs, and the President gets to declare a victory for the American people. Everyone wins, especially those who enjoy a good deal on their insulin and a side of tariff immunity. Analysts, however, remain skeptical, noting that Medicaid already enjoys substantial discounts and these new deals could lead to “price and margin compression” for the industry. But hey, optics!
Nvidia’s Chinese Gambit: Chips, Cuts, and Geopolitical Headaches
In a twist that could only happen in the current geopolitical climate, the U.S. government decided to play a game of “will they, won’t they” with Nvidia (NVDA) and its advanced AI chips for China. After a period of tightened restrictions, President Trump greenlighted the export of NVDA‘s H200 chips to “approved” Chinese customers. The catch? The U.S. government gets a 25% revenue cut from these sales. Because nothing says free markets like the government taking a quarter of your international sales.
This policy reversal, which undid Biden-era restrictions, was met with predictable market enthusiasm. NVDA closed Monday, December 15, up 0.73% at $176.29, fueled by reports of strong H200 demand from China. By December 19, NVDA shares were up about 3% at $183.40 in early trading, as investors reacted to signs of official U.S. approval for chip exports to China. Despite gaining 1.9% on Thursday, December 18, the stock remains down roughly 1.4% over the past three months, reflecting persistent investor caution around China exposure and export restrictions. Analysts, ever the optimists, believe that reopening the Chinese market “reduces significant downside risks” for NVDA. One can only imagine the boardroom discussions: “How much national security are we willing to trade for a 25% cut of a multi-billion dollar market?” The answer, apparently, is “quite a bit.”
The Economy: It’s Complicated
While the market has been doing its usual dance of exuberance and despair, the broader economic picture remains, shall we say, nuanced. Despite the Dow, S&P 500, and Nasdaq all rising by 13% to 20% year-to-date through December 16, 2025, and AI investments driving “unprecedented growth”, the average American seems less than thrilled. President Trump’s approval rating on the economy has plummeted to its lowest point in either of his terms, hovering between 31-39% in December 2025 polls. A staggering seven in ten Americans describe the nation’s economy as “poor”, even as inflation runs at 2.7% and unemployment rose to 4.6% in November.
Perhaps the “Warrior Dividend” checks of $1,776, announced by Trump, were meant to soothe these economic anxieties. While no direct market reaction to this specific announcement was found, it’s clear that the public’s perception of economic well-being is diverging from the headline stock market numbers. The Federal Open Market Committee (FOMC) has been busy cutting interest rates in each of its last three meetings, presumably to stimulate an economy that many Americans feel isn’t working for them. It’s a tale of two economies: one soaring on AI and presidential pronouncements, the other grappling with rising prices and a general sense of malaise. And in this market, the only constant is the expectation of the unexpected, preferably delivered via a 280-character missive.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.